These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
359 related items for PubMed ID: 22523546
1. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z, Luo H. PLoS One; 2012; 7(4):e34210. PubMed ID: 22523546 [Abstract] [Full Text] [Related]
2. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients. Kassem NM, Makar WS, Kassem HA, Talima S, Tarek M, Hesham H, El-Desouky MA. Asian Pac J Cancer Prev; 2019 Sep 01; 20(9):2749-2755. PubMed ID: 31554373 [Abstract] [Full Text] [Related]
3. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Liu B, Su F, Chen M, Li Y, Qi X, Xiao J, Li X, Liu X, Liang W, Zhang Y, Zhang J. Hum Pathol; 2017 Jun 01; 64():44-52. PubMed ID: 28412211 [Abstract] [Full Text] [Related]
4. miR-125b regulates side population in breast cancer and confers a chemoresistant phenotype. Wang HJ, Guo YQ, Tan G, Dong L, Cheng L, Li KJ, Wang ZY, Luo HF. J Cell Biochem; 2013 Oct 01; 114(10):2248-57. PubMed ID: 23606360 [Abstract] [Full Text] [Related]
5. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer. Shao B, Wang X, Zhang L, Li D, Liu X, Song G, Cao H, Zhu J, Li H. Technol Cancer Res Treat; 2019 Jan 01; 18():1533033819828709. PubMed ID: 30786836 [Abstract] [Full Text] [Related]
11. Prognostic Significance of Serum miR-22, miR-125b, and miR-15b in Non-Small Cell Lung Cancer Patients. Shi GL, Zhang XY, Chen Y, Ma S, Bai WQ, Yin YJ. Clin Lab; 2020 Jun 01; 66(6):. PubMed ID: 32538046 [Abstract] [Full Text] [Related]
12. The lncRNA XIST/miR-125b-2-3p axis modulates cell proliferation and chemotherapeutic sensitivity via targeting Wee1 in colorectal cancer. Zeng ZL, Lu JH, Wang Y, Sheng H, Wang YN, Chen ZH, Wu QN, Zheng JB, Chen YX, Yang DD, Yu K, Mo HY, Hu JJ, Hu PS, Liu ZX, Ju HQ, Xu RH. Cancer Med; 2021 Apr 01; 10(7):2423-2441. PubMed ID: 33666372 [Abstract] [Full Text] [Related]
16. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer. Zhang Z, Zhang H, Li C, Xiang Q, Xu L, Liu Q, Pang X, Zhang W, Zhang H, Zhang S, Duan X, Liu Y, Cui Y. Thorac Cancer; 2021 Dec 01; 12(24):3396-3406. PubMed ID: 34751517 [Abstract] [Full Text] [Related]
17. Response Assessment With Molecular Characterization of Circulating Tumor Cells and Plasma MicroRNA Profiling in Patients With Locally Advanced Breast Cancer During Neoadjuvant Chemotherapy. Akkiprik M, Koca S, Uğurlu MÜ, Ekren R, Peker Eyüboğlu İ, Alan Ö, Erzik C, Güllü Amuran G, Telli TA, Güllüoğlu MB, Sezerman U, Yumuk PF. Clin Breast Cancer; 2020 Aug 01; 20(4):332-343.e3. PubMed ID: 32201164 [Abstract] [Full Text] [Related]
20. The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H, Zhang S, Hong R, Gu X. Tumour Biol; 2015 Sep 01; 36(9):7185-94. PubMed ID: 25894378 [Abstract] [Full Text] [Related] Page: [Next] [New Search]